首页 > 最新文献

Atla-Alternatives To Laboratory Animals最新文献

英文 中文
2022 Michael Balls Award. 2022年迈克尔鲍尔斯奖。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-07-01 DOI: 10.1177/02611929231180455
{"title":"2022 Michael Balls Award.","authors":"","doi":"10.1177/02611929231180455","DOIUrl":"https://doi.org/10.1177/02611929231180455","url":null,"abstract":"","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 4","pages":"222-223"},"PeriodicalIF":2.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9855769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Animal Models and Cutting-Edge Research in Alternatives: Proceedings of the Third International Conference on 3Rs Research and Progress, Vishakhapatnam, 2022. 动物模型的进展和替代品的前沿研究:第三届3Rs研究与进展国际会议论文集,Vishakhapatnam, 2022。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-07-01 DOI: 10.1177/02611929231180428
Nikita Narayan Naik, Bharadwaja Vadloori, Suresh Poosala, Pratima Srivastava, Sandra Coecke, Adrian Smith, Aysha Akhtar, Clive Roper, Sridhar Radhakrishnan, Balaji Bhyravbhatla, Madhujit Damle, Venkat Koushik Pulla, Johannes Hackethal, Reyk Horland, Albert P Li, Falguni Pati, Manu Smriti Singh, Paola Occhetta, Rohit Bisht, Prajakta Dandekar, Krishna Bhagavatula, Dasja Pajkrt, Michael Johnson, Tilo Weber, John Huang, Lisiena Hysenaj, Banerjee Mallar, Bhat Ramray, Santosh Dixit, Shreekanth Joshi, Mandar Kulkarni

Animal experimentation has been integral to drug discovery and development and safety assessment for many years, since it provides insights into the mechanisms of drug efficacy and toxicity (e.g. pharmacology, pharmacokinetics and pharmacodynamics). However, due to species differences in physiology, metabolism and sensitivity to drugs, the animal models can often fail to replicate the effects of drugs and chemicals in human patients, workers and consumers. Researchers across the globe are increasingly applying the Three Rs principles by employing innovative methods in research and testing. The Three Rs concept focuses on: the replacement of animal models (e.g. with in vitro and in silico models or human studies), on the reduction of the number of animals required to achieve research objectives, and on the refinement of existing experimental practices (e.g. eliminating distress and enhancing animal wellbeing). For the last two years, Oncoseek Bio-Acasta Health, a 3-D cell culture-based cutting-edge translational biotechnology company, has organised an annual International Conference on 3Rs Research and Progress. This series of global conferences aims to bring together researchers with diverse expertise and interests, and provides a platform where they can share and discuss their research to promote practices according to the Three Rs principles. In November 2022, the 3rd international conference, Advances in Animal Models and Cutting-Edge Research in Alternatives, took place at the GITAM University in Vishakhapatnam (AP, India) in a hybrid format (i.e. online and in-person). These conference proceedings provide details of the presentations, which were categorised under five different topic sessions. It also describes a special interactive session on in silico strategies for preclinical research in oncology, which was held at the end of the first day.

多年来,动物实验一直是药物发现、开发和安全性评估的组成部分,因为它提供了对药物疗效和毒性机制的见解(例如药理学、药代动力学和药效学)。然而,由于物种在生理、代谢和药物敏感性方面的差异,动物模型往往无法在人类患者、工人和消费者身上复制药物和化学物质的效果。全球的研究人员越来越多地在研究和测试中采用创新的方法来应用“三个r”原则。“3r”概念侧重于:替代动物模型(例如,用体外和计算机模型或人体研究),减少实现研究目标所需的动物数量,以及改进现有的实验实践(例如,消除痛苦和提高动物福利)。在过去的两年里,Oncoseek Bio-Acasta Health,一家以3d细胞培养为基础的尖端转化生物技术公司,组织了一年一度的3r研究与进展国际会议。这一系列全球会议旨在汇集具有不同专业知识和兴趣的研究人员,并提供一个平台,让他们可以分享和讨论他们的研究,以促进根据“三个r”原则的实践。2022年11月,第三届国际会议“动物模型的进展和替代方案的前沿研究”以混合形式(即在线和面对面)在印度维沙卡帕特南的GITAM大学举行。这些会议记录提供了演讲的细节,这些演讲被分为五个不同的主题会议。它还描述了在第一天结束时举行的关于肿瘤临床前研究的计算机策略的特别互动会议。
{"title":"Advances in Animal Models and Cutting-Edge Research in Alternatives: Proceedings of the Third International Conference on 3Rs Research and Progress, Vishakhapatnam, 2022.","authors":"Nikita Narayan Naik,&nbsp;Bharadwaja Vadloori,&nbsp;Suresh Poosala,&nbsp;Pratima Srivastava,&nbsp;Sandra Coecke,&nbsp;Adrian Smith,&nbsp;Aysha Akhtar,&nbsp;Clive Roper,&nbsp;Sridhar Radhakrishnan,&nbsp;Balaji Bhyravbhatla,&nbsp;Madhujit Damle,&nbsp;Venkat Koushik Pulla,&nbsp;Johannes Hackethal,&nbsp;Reyk Horland,&nbsp;Albert P Li,&nbsp;Falguni Pati,&nbsp;Manu Smriti Singh,&nbsp;Paola Occhetta,&nbsp;Rohit Bisht,&nbsp;Prajakta Dandekar,&nbsp;Krishna Bhagavatula,&nbsp;Dasja Pajkrt,&nbsp;Michael Johnson,&nbsp;Tilo Weber,&nbsp;John Huang,&nbsp;Lisiena Hysenaj,&nbsp;Banerjee Mallar,&nbsp;Bhat Ramray,&nbsp;Santosh Dixit,&nbsp;Shreekanth Joshi,&nbsp;Mandar Kulkarni","doi":"10.1177/02611929231180428","DOIUrl":"https://doi.org/10.1177/02611929231180428","url":null,"abstract":"<p><p>Animal experimentation has been integral to drug discovery and development and safety assessment for many years, since it provides insights into the mechanisms of drug efficacy and toxicity (e.g. pharmacology, pharmacokinetics and pharmacodynamics). However, due to species differences in physiology, metabolism and sensitivity to drugs, the animal models can often fail to replicate the effects of drugs and chemicals in human patients, workers and consumers. Researchers across the globe are increasingly applying the Three Rs principles by employing innovative methods in research and testing. The Three Rs concept focuses on: the <i>replacement</i> of animal models (e.g. with <i>in vitro</i> and <i>in silico</i> models or human studies), on the <i>reduction</i> of the number of animals required to achieve research objectives, and on the <i>refinement</i> of existing experimental practices (e.g. eliminating distress and enhancing animal wellbeing). For the last two years, Oncoseek Bio-Acasta Health, a 3-D cell culture-based cutting-edge translational biotechnology company, has organised an annual International Conference on 3Rs Research and Progress. This series of global conferences aims to bring together researchers with diverse expertise and interests, and provides a platform where they can share and discuss their research to promote practices according to the Three Rs principles. In November 2022, the 3rd international conference, <i>Advances in Animal Models and Cutting-Edge Research in Alternatives</i>, took place at the GITAM University in Vishakhapatnam (AP, India) in a hybrid format (i.e. online and in-person). These conference proceedings provide details of the presentations, which were categorised under five different topic sessions. It also describes a special interactive session on <i>in silico</i> strategies for preclinical research in oncology, which was held at the end of the first day.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 4","pages":"263-288"},"PeriodicalIF":2.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10231991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Fenugreek Seed Extract Regulates Human Umbilical Vein Endothelial Cell Angiogenesis and Proliferation via the PI3K/Akt/Cyclin D1 Pathway. 胡芦巴籽提取物通过PI3K/Akt/细胞周期蛋白D1途径调节人脐静脉内皮细胞的血管生成和增殖。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-07-01 Epub Date: 2023-06-22 DOI: 10.1177/02611929231181623
Samaneh Safarpour, Farshad Mirzavi, Farzad Rahmani, Fatemeh Forouzanfar, Hamid Reza Sadeghnia, Baratali Mashkani, Daryoush Hamidi Alamdari, Mohammad Soukhtanloo

The significance of angiogenesis in tumour progression has been widely documented. Hence, the identification of anti-angiogenic agents with fewer common side effects would be valuable in cancer therapy. In this study, we evaluated the anti-angiogenic and anti-proliferative effects of a hydro-alcoholic extract of fenugreek seed (HAEF) on human umbilical vein endothelial cells (HUVECs). Human umbilical vein endothelial cells were treated with various concentrations of HAEF and the half-maximal inhibitory concentration (IC50) value was estimated by using the MTT assay. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and matrix metalloproteinase enzyme (MMP-2 and MMP-9) gene expression profiles were evaluated by using quantitative RT-PCR (qRT-PCR). Moreover, MMP activities and PI3K, Akt and cyclin D1 protein expression levels were evaluated by gel zymography and Western blotting, respectively. HAEF reduced HUVEC viability, with an IC50 value of 200 μg/ml. The qRT-PCR results demonstrated that treatment with HAEF markedly reduced MMP-2/MMP-9, VEGF and bFGF gene expression, as compared to the control group. We also found that MMP-2/MMP-9 enzyme activity and PI3K/Akt/cyclin D1 protein expression were notably decreased in cells treated with HAEF. Our results suggest that HAEF can potentially inhibit angiogenesis, and also affect cellular proliferation by targeting the PI3K/Akt/cyclin D1 pathway. Thus, fenugreek seed extract merits further investigation as a source of compounds with anti-cancer properties.

血管生成在肿瘤进展中的重要性已被广泛记录。因此,识别具有较少常见副作用的抗血管生成药物在癌症治疗中是有价值的。在本研究中,我们评估了胡芦巴种子水醇提取物(HAEF)对人脐静脉内皮细胞(HUVECs)的抗血管生成和抗增殖作用。用不同浓度的HAEF处理人脐静脉内皮细胞,并通过MTT法估计半数最大抑制浓度(IC50)值。采用定量RT-PCR(qRT-PCR)检测血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)和基质金属蛋白酶(MMP-2和MMP-9)基因表达谱。此外,MMP活性和PI3K、Akt和细胞周期蛋白D1蛋白表达水平分别通过凝胶酶谱法和蛋白质印迹法进行评估。HAEF降低HUVEC活力,IC50值为200μg/ml。qRT-PCR结果表明,与对照组相比,HAEF治疗显著降低了MMP-2/MMP-9、VEGF和bFGF基因的表达。我们还发现,在用HAEF处理的细胞中,MMP-2/MMP-9酶活性和PI3K/Akt/细胞周期蛋白D1蛋白表达显著降低。我们的研究结果表明,HAEF可以潜在地抑制血管生成,并通过靶向PI3K/Akt/细胞周期蛋白D1途径影响细胞增殖。因此,胡芦巴种子提取物作为具有抗癌特性的化合物的来源值得进一步研究。
{"title":"Fenugreek Seed Extract Regulates Human Umbilical Vein Endothelial Cell Angiogenesis and Proliferation via the PI3K/Akt/Cyclin D1 Pathway.","authors":"Samaneh Safarpour,&nbsp;Farshad Mirzavi,&nbsp;Farzad Rahmani,&nbsp;Fatemeh Forouzanfar,&nbsp;Hamid Reza Sadeghnia,&nbsp;Baratali Mashkani,&nbsp;Daryoush Hamidi Alamdari,&nbsp;Mohammad Soukhtanloo","doi":"10.1177/02611929231181623","DOIUrl":"10.1177/02611929231181623","url":null,"abstract":"<p><p>The significance of angiogenesis in tumour progression has been widely documented. Hence, the identification of anti-angiogenic agents with fewer common side effects would be valuable in cancer therapy. In this study, we evaluated the anti-angiogenic and anti-proliferative effects of a hydro-alcoholic extract of fenugreek seed (HAEF) on human umbilical vein endothelial cells (HUVECs). Human umbilical vein endothelial cells were treated with various concentrations of HAEF and the half-maximal inhibitory concentration (IC<sub>50</sub>) value was estimated by using the MTT assay. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and matrix metalloproteinase enzyme (MMP-2 and MMP-9) gene expression profiles were evaluated by using quantitative RT-PCR (qRT-PCR). Moreover, MMP activities and PI3K, Akt and cyclin D1 protein expression levels were evaluated by gel zymography and Western blotting, respectively. HAEF reduced HUVEC viability, with an IC<sub>50</sub> value of 200 μg/ml. The qRT-PCR results demonstrated that treatment with HAEF markedly reduced MMP-2/MMP-9, VEGF and bFGF gene expression, as compared to the control group. We also found that MMP-2/MMP-9 enzyme activity and PI3K/Akt/cyclin D1 protein expression were notably decreased in cells treated with HAEF. Our results suggest that HAEF can potentially inhibit angiogenesis, and also affect cellular proliferation by targeting the PI3K/Akt/cyclin D1 pathway. Thus, fenugreek seed extract merits further investigation as a source of compounds with anti-cancer properties.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 4","pages":"249-257"},"PeriodicalIF":2.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10206735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Spotlight on Three Rs Progress. 聚焦“三个r”进展。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-07-01 DOI: 10.1177/02611929231180502
The FRAME Innovation Grant funding stream provides small grants for studies that will support the replacement of animals in biomedical research. FRAME launched the annual Innovation Grant scheme in 2021 to address a gap in the availability of small funding pots for proof-of-principle research and pilot projects. The scheme offers grants of around £5000, but will consider applications asking for up to £15,000. Projects should last between six months and two years. The first two years of this scheme proved to be very popular and resulted in the funding of some diverse and interesting projects. The grants represent a pilot project funding stream, to enable scientists to explore innovative ideas, methods and techniques and, where relevant, to generate proof-ofprinciple data to support applications for larger grants in the future. All applications for funding will be assessed by a panel of academics, FRAME staff and, where possible, an expert in the relevant field, according to the following key criteria:
{"title":"Spotlight on Three Rs Progress.","authors":"","doi":"10.1177/02611929231180502","DOIUrl":"https://doi.org/10.1177/02611929231180502","url":null,"abstract":"The FRAME Innovation Grant funding stream provides small grants for studies that will support the replacement of animals in biomedical research. FRAME launched the annual Innovation Grant scheme in 2021 to address a gap in the availability of small funding pots for proof-of-principle research and pilot projects. The scheme offers grants of around £5000, but will consider applications asking for up to £15,000. Projects should last between six months and two years. The first two years of this scheme proved to be very popular and resulted in the funding of some diverse and interesting projects. The grants represent a pilot project funding stream, to enable scientists to explore innovative ideas, methods and techniques and, where relevant, to generate proof-ofprinciple data to support applications for larger grants in the future. All applications for funding will be assessed by a panel of academics, FRAME staff and, where possible, an expert in the relevant field, according to the following key criteria:","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 4","pages":"217-219"},"PeriodicalIF":2.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10231972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial. 社论。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-05-01 DOI: 10.1177/02611929231175315
Changes to cosmetics regulations internationally have been instrumental in the move away from animal testing and toward the development and promotion of alternative methods. Brazil is one of the largest markets for personal care and cosmetics products in the world and on 1st March 2023, as Resolution No. 58/2023 came into force, Brazil joined over 40 countries moving towards a global ban on the testing of cosmetic ingredients on animals. It is encouraging to witness not only the ongoing progress in governmental policies in mandating alternatives to animals, but also the continual innovations in the associated science. Whilst, currently, there is significant focus on applications in cosmetics, success in this arena will undoubtedly drive forward the use and acceptance of alternatives in other areas. Further details on the Brazilian Resolution are given in the Spotlight on Three Rs Progress section of this issue. This section also includes summaries of different studies that are applying a diverse range of alternative methods, from bioprinting of reconstructed human epidermis for assessing skin irritation, to open-source software that can quantify animal behaviours. Studies on the effects of SARSCoV-2 on the developing fetal brain and a model for human ovarian follicles are also highlighted. The review article by da Silva and Valadares also focuses attention on SARS-CoV-2 and how the pandemic highlighted the need for improvements in non-animal based methods in preclinical research for respiratory diseases. Here, the authors provide a detailed review of key methods that can be applied in this area, including: monolayer cell cultures; air–liquid interface models; lung organoids; human precision-cut lung slices (PCLS); and lung-on-a-chip microfluidic systems. The advantages and limitations of each method are discussed, as well as the need for standardisation and quality control procedures to make these New Approach Methodologies (NAMs) more acceptable for regulatory purposes. The importance of selecting the most appropriate models and endpoints to measure, depending on the research question, is emphasised. Andersson et al. also propose an addition to what they describe as the “NAM-based predictive toolbox”. These authors report an in silicomethod that can be used to differentiate liquids with the potential for eliciting eye irritation, from those considered to be non-irritant. The authors describe a two-tier approach that identifies potential irritants by using predicted pKa values and also by using a model that is derived from Hansen Solubility Parameters. The model performed well, and in order to err on the side of caution, it has been optimised to give a low rate of false negative predictions. The last two articles in this issue both present results from assays for toxicity testing. Hautenen et al. present the results of a study to develop an assay to assess the induction of vasculature formation — a mechanism associated with non-genotoxic carcinog
{"title":"Editorial.","authors":"","doi":"10.1177/02611929231175315","DOIUrl":"https://doi.org/10.1177/02611929231175315","url":null,"abstract":"Changes to cosmetics regulations internationally have been instrumental in the move away from animal testing and toward the development and promotion of alternative methods. Brazil is one of the largest markets for personal care and cosmetics products in the world and on 1st March 2023, as Resolution No. 58/2023 came into force, Brazil joined over 40 countries moving towards a global ban on the testing of cosmetic ingredients on animals. It is encouraging to witness not only the ongoing progress in governmental policies in mandating alternatives to animals, but also the continual innovations in the associated science. Whilst, currently, there is significant focus on applications in cosmetics, success in this arena will undoubtedly drive forward the use and acceptance of alternatives in other areas. Further details on the Brazilian Resolution are given in the Spotlight on Three Rs Progress section of this issue. This section also includes summaries of different studies that are applying a diverse range of alternative methods, from bioprinting of reconstructed human epidermis for assessing skin irritation, to open-source software that can quantify animal behaviours. Studies on the effects of SARSCoV-2 on the developing fetal brain and a model for human ovarian follicles are also highlighted. The review article by da Silva and Valadares also focuses attention on SARS-CoV-2 and how the pandemic highlighted the need for improvements in non-animal based methods in preclinical research for respiratory diseases. Here, the authors provide a detailed review of key methods that can be applied in this area, including: monolayer cell cultures; air–liquid interface models; lung organoids; human precision-cut lung slices (PCLS); and lung-on-a-chip microfluidic systems. The advantages and limitations of each method are discussed, as well as the need for standardisation and quality control procedures to make these New Approach Methodologies (NAMs) more acceptable for regulatory purposes. The importance of selecting the most appropriate models and endpoints to measure, depending on the research question, is emphasised. Andersson et al. also propose an addition to what they describe as the “NAM-based predictive toolbox”. These authors report an in silicomethod that can be used to differentiate liquids with the potential for eliciting eye irritation, from those considered to be non-irritant. The authors describe a two-tier approach that identifies potential irritants by using predicted pKa values and also by using a model that is derived from Hansen Solubility Parameters. The model performed well, and in order to err on the side of caution, it has been optimised to give a low rate of false negative predictions. The last two articles in this issue both present results from assays for toxicity testing. Hautenen et al. present the results of a study to develop an assay to assess the induction of vasculature formation — a mechanism associated with non-genotoxic carcinog","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 3","pages":"155-156"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9570332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spotlight on Three Rs Progress. 聚焦“三个r”进展。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-05-01 DOI: 10.1177/02611929231170668
The Brazilian National Council for the Control of Animal Experimentation (CONCEA) has prohibited the use of animals, except human beings, in research for the development of cosmetics, hygiene products and perfumes. CONCEA is linked to the Ministry of Science and Technology, and the decision was published in the Brazilian Official Gazette on 1 March 2023. The measure states that it is mandatory, in Brazil, to adopt alternative methods that reduce the use of animals in this type of studies, stating that: “The use of vertebrate animals, except human beings, in scientific research and in the development and quality control of personal hygiene products, cosmetics, and perfumes that use in their formulations ingredients or compounds with safety and efficacy already scientifically proven is prohibited.” This approval follows the publication of a series of normative resolutions by the council over the last years recognising the applications of alternative methods that could replace animal testing.
{"title":"Spotlight on Three Rs Progress.","authors":"","doi":"10.1177/02611929231170668","DOIUrl":"https://doi.org/10.1177/02611929231170668","url":null,"abstract":"The Brazilian National Council for the Control of Animal Experimentation (CONCEA) has prohibited the use of animals, except human beings, in research for the development of cosmetics, hygiene products and perfumes. CONCEA is linked to the Ministry of Science and Technology, and the decision was published in the Brazilian Official Gazette on 1 March 2023. The measure states that it is mandatory, in Brazil, to adopt alternative methods that reduce the use of animals in this type of studies, stating that: “The use of vertebrate animals, except human beings, in scientific research and in the development and quality control of personal hygiene products, cosmetics, and perfumes that use in their formulations ingredients or compounds with safety and efficacy already scientifically proven is prohibited.” This approval follows the publication of a series of normative resolutions by the council over the last years recognising the applications of alternative methods that could replace animal testing.","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 3","pages":"157-158"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9938328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conference Diary. 会议的日记。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-05-01 DOI: 10.1177/02611929231170669
{"title":"Conference Diary.","authors":"","doi":"10.1177/02611929231170669","DOIUrl":"https://doi.org/10.1177/02611929231170669","url":null,"abstract":"","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 3","pages":"210-211"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9938327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resources Round-up. 资源聚集。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-05-01 DOI: 10.1177/02611929231170667
{"title":"Resources Round-up.","authors":"","doi":"10.1177/02611929231170667","DOIUrl":"https://doi.org/10.1177/02611929231170667","url":null,"abstract":"","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 3","pages":"159-160"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Silico Prediction of Eye Irritation Using Hansen Solubility Parameters and Predicted pKa Values. 用汉森溶解度参数和预测pKa值预测眼部刺激。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-05-01 DOI: 10.1177/02611929231175676
Martin Andersson, Ulf Norinder, Swapnil Chavan, Ian Cotgreave

An in silico method has been developed that permits the binary differentiation between pure liquids causing serious eye damage or eye irritation, and pure liquids with no need for such classification, according to the UN GHS system. The method is based on the finding that the Hansen Solubility Parameters (HSP) of a liquid are collectively important predictors for eye irritation. Thus, by applying a two-tier approach in which in silico-predicted pKa values (firstly) and a trained model based solely on in silico-predicted HSP data (secondly) were used, we have developed, and validated, a fully in silico approach for predicting the outcome of a Draize test (in terms of UN GHS Cat. 1/Cat. 2A/Cat. 2B or UN GHS No Cat.) with high validation set performance (sensitivity = 0.846, specificity = 0.818, balanced accuracy = 0.832) using SMILES only. The method is applicable to pure non-ionic liquids with molecular weight below 500 g/mol, fewer than six hydrogen bond donors (e.g. nitrogen-hydrogen or oxygen-hydrogen bonds) and fewer than eleven hydrogen bond acceptors (e.g. nitrogen or oxygen atoms). Due to its fully in silico characteristics, this method can be applied to pure liquids that are still at the desktop design stage and not yet in production.

根据联合国GHS系统,一种计算机方法已经开发出来,可以将造成严重眼睛损伤或眼睛刺激的纯液体与无需进行此类分类的纯液体进行二元区分。该方法是基于发现液体的汉森溶解度参数(HSP)是对眼睛刺激的重要预测因素。因此,通过应用两层方法(首先是计算机预测的pKa值)和仅基于计算机预测的HSP数据(其次)的训练模型(第二层),我们开发并验证了一种完全计算机化的方法,用于预测Draize测试的结果(根据联合国GHS Cat. 1/Cat. 1)。2 /猫。b或UN GHS No Cat),仅使用SMILES即可获得高验证集性能(灵敏度= 0.846,特异性= 0.818,平衡准确性= 0.832)。该方法适用于分子量低于500g /mol,氢键供体(如氮-氢或氧-氢键)少于6个,氢键受体(如氮或氧原子)少于11个的纯非离子液体。由于其完全的硅化特性,该方法可以应用于仍处于桌面设计阶段且尚未投入生产的纯液体。
{"title":"<i>In Silico</i> Prediction of Eye Irritation Using Hansen Solubility Parameters and Predicted pKa Values.","authors":"Martin Andersson,&nbsp;Ulf Norinder,&nbsp;Swapnil Chavan,&nbsp;Ian Cotgreave","doi":"10.1177/02611929231175676","DOIUrl":"https://doi.org/10.1177/02611929231175676","url":null,"abstract":"<p><p>An <i>in silico</i> method has been developed that permits the binary differentiation between pure liquids causing serious eye damage or eye irritation, and pure liquids with no need for such classification, according to the UN GHS system. The method is based on the finding that the Hansen Solubility Parameters (HSP) of a liquid are collectively important predictors for eye irritation. Thus, by applying a two-tier approach in which <i>in silico</i>-predicted pKa values (firstly) and a trained model based solely on <i>in silico</i>-predicted HSP data (secondly) were used, we have developed, and validated, a fully <i>in silico</i> approach for predicting the outcome of a Draize test (in terms of UN GHS Cat. 1/Cat. 2A/Cat. 2B or UN GHS No Cat.) with high validation set performance (sensitivity = 0.846, specificity = 0.818, balanced accuracy = 0.832) using SMILES only. The method is applicable to pure non-ionic liquids with molecular weight below 500 g/mol, fewer than six hydrogen bond donors (e.g. nitrogen-hydrogen or oxygen-hydrogen bonds) and fewer than eleven hydrogen bond acceptors (e.g. nitrogen or oxygen atoms). Due to its fully <i>in silico</i> characteristics, this method can be applied to pure liquids that are still at the desktop design stage and not yet in production.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 3","pages":"204-209"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9625352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Application of New Approach Methodologies in Respiratory Disease Research: Their Role in Improving Translational Medicine from Bench to Bedside. 新方法方法在呼吸系统疾病研究中的应用:它们在提高从实验室到床边的转化医学中的作用。
IF 2.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-05-01 DOI: 10.1177/02611929231170392
Artur C G da Silva, Marize C Valadares

The SARS-CoV-2 outbreak focused global attention on the shortcomings of the drug discovery process. It led to its acceleration in several areas, particularly in the processes associated with the development and approval of COVID-19 vaccines. This situation contrasts with the low approval rates of new drugs for respiratory system diseases (e.g. asthma, chronic obstructive pulmonary disease, cancer, tuberculosis), which are leading causes of morbidity and mortality worldwide. In this context, innovation in respiratory system drug discovery is surely needed, and it is most likely to succeed through the use of preclinical models that are cost-effective, high-throughput and generate predictive human-relevant outcomes. Here, we highlight several non-animal new approach methodologies (NAMs) and their applications in respiratory research. We describe their potential uses for efficacy and toxicity assessments, to optimise the drug development process and reduce the high failure rates in clinical trials.

SARS-CoV-2疫情使全球注意力集中在药物发现过程的缺陷上。它加速了若干领域的进展,特别是与COVID-19疫苗开发和批准相关的进程。这种情况与呼吸系统疾病(如哮喘、慢性阻塞性肺病、癌症、结核病)新药的低批准率形成鲜明对比,这些疾病是全世界发病率和死亡率的主要原因。在这种情况下,呼吸系统药物发现的创新肯定是必要的,并且通过使用具有成本效益,高通量和产生预测性人类相关结果的临床前模型最有可能取得成功。在此,我们重点介绍几种非动物新方法及其在呼吸研究中的应用。我们描述了它们在功效和毒性评估方面的潜在用途,以优化药物开发过程并降低临床试验中的高失败率。
{"title":"The Application of New Approach Methodologies in Respiratory Disease Research: Their Role in Improving Translational Medicine from Bench to Bedside.","authors":"Artur C G da Silva,&nbsp;Marize C Valadares","doi":"10.1177/02611929231170392","DOIUrl":"https://doi.org/10.1177/02611929231170392","url":null,"abstract":"<p><p>The SARS-CoV-2 outbreak focused global attention on the shortcomings of the drug discovery process. It led to its acceleration in several areas, particularly in the processes associated with the development and approval of COVID-19 vaccines. This situation contrasts with the low approval rates of new drugs for respiratory system diseases (e.g. asthma, chronic obstructive pulmonary disease, cancer, tuberculosis), which are leading causes of morbidity and mortality worldwide. In this context, innovation in respiratory system drug discovery is surely needed, and it is most likely to succeed through the use of preclinical models that are cost-effective, high-throughput and generate predictive human-relevant outcomes. Here, we highlight several non-animal new approach methodologies (NAMs) and their applications in respiratory research. We describe their potential uses for efficacy and toxicity assessments, to optimise the drug development process and reduce the high failure rates in clinical trials.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"51 3","pages":"161-174"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9926909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Atla-Alternatives To Laboratory Animals
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1